In this article
The short answer
No. The CPNP does not check whether your product is safe. The portal makes sure the mandatory fields are filled in, and that is all; nobody at the Commission or in a Member State reviews your formula or your safety report when you notify. Safety rests on the Cosmetic Product Safety Report (CPSR), which Article 10 of Regulation (EC) No 1223/2009 requires before the product is placed on the market, signed off by a qualified safety assessor. The notification tells competent authorities and poison centres that the product exists, who is responsible for it and where the Product Information File is kept. Your CPSR gets read later, when a complaint, a reaction report or a surveillance check brings an authority to that address.
Key takeaways
- The CPNP is a register, not a safety review. The Commission's own CPNP guide says a successful notification does not mean the product meets the Regulation.
- The CPSR must exist before the product is placed on the market (Article 10). It is never uploaded to the CPNP; it sits in the Product Information File at the Responsible Person's address.
- Several notification fields copy the safety assessment: the formulation, CMR substances, nanomaterials, product category, and the warnings on the label you upload. Assess first, notify second.
- Competent authorities use the CPNP to find you; poison centres use it to treat patients. When an authority wants to judge safety, it asks for your file (Articles 22 and 25).
- Nanomaterials are the exception: under Article 16 most need a separate notification with safety data six months before launch, and the SCCS can be asked to review them.
- A product can be perfectly safe and still have an inadequate assessment. That is a breach in itself, and authorities can order corrective action, withdrawal or recall.
Every few weeks a founder sends us a screenshot of a CPNP reference number with the same question attached: "So we're safe to sell, right?" Sometimes it is hope, because they thought notification was a kind of approval. Sometimes it is worry, because they think a regulator is now going through their formula line by line. Neither is true, and the real answer matters more than either.
The CPNP does not check product safety. Nobody reviews your formula, your test results or your safety report when you press Notify. That puts the whole weight of product safety on one document many brands have never properly read: the Cosmetic Product Safety Report. This article is about how the two connect, and why the order you do them in shapes how an inspection goes. If you need the portal basics first, read what the CPNP is. For the paperwork side (reference numbers, "registration" and what to tell a buyer), see why notification is not approval.
Does the CPNP check product safety? What the portal actually checks
When you submit a notification, the portal checks that the mandatory fields are complete and in the right format. It will stop you if you skip the category or forget the contact person. It will not tell you that your preservative is over its Annex V limit, that your fragrance allergens need labelling, or that your "gentle baby balm" has never been assessed for use on under-threes.
The Commission is blunt about this. Its guide to using the CPNP says that a successful notification "does not imply" the product fulfils the requirements of Regulation (EC) No 1223/2009, and that the Responsible Person has to make sure it does. There is no approval step, no officer assigned to your file and no certificate at the end.
Here is how the two obligations compare side by side.
| CPNP notification | CPSR (safety assessment) | |
|---|---|---|
| Legal basis | Article 13 (plus Article 16 for most nanomaterials) | Article 10 and Annex I |
| Who prepares it | The Responsible Person, usually in an afternoon | A qualified safety assessor, using data you and your suppliers provide |
| When | Before the product is placed on the market; labelling once it is | Before the product is placed on the market, then kept up to date |
| Where it goes | The Commission's portal | The Product Information File, at the Responsible Person's address |
| Who reads it | Competent authorities (market surveillance) and poison centres (medical treatment) | A competent authority, when it asks for the file |
| What it shows | That the product exists and who answers for it | That the product is safe under normal and reasonably foreseeable use (Article 3) |
| Reviewed when submitted? | No | No. It is judged when someone asks for it |
Where product safety is actually decided: the CPSR
Article 3 says a cosmetic must be safe under normal or reasonably foreseeable conditions of use. Article 10 is how you show it. Before the product is placed on the market, the Responsible Person must make sure it has had a safety assessment and that a CPSR has been set up in line with Annex I. The report then has to be kept up to date as new information comes in, such as complaints, reformulations or a change to an ingredient's restrictions.
Annex I splits the report in two. Part A gathers the data: composition, physical and chemical characteristics and stability, microbiological quality, impurities and packaging, normal and foreseeable use, exposure to the product and to each substance, toxicological profiles, undesirable effects, and anything else relevant. Part B is the assessor's conclusion, the label warnings and instructions they require, their reasoning, and their credentials. The Commission's Annex I guidelines (Implementing Decision 2013/674/EU) explain what each section should contain.
Part B can only be signed by someone with a diploma or equivalent qualification from a university course in pharmacy, toxicology, medicine or a similar discipline, or a course a Member State recognises as equivalent (Article 10(2)). That signature is the only point in the whole EU system where a qualified person looks at your product and says whether it is safe. A good assessor will ask awkward questions. A report that arrives with no questions at all should worry you. Our explainers on CPSR Part A, CPSR Part B and the margin of safety go deeper.
The one place safety data does reach the Commission
Nanomaterials. Under Article 16, most products containing a nanomaterial need a separate notification six months before they go on sale, with the material's specification, toxicological profile and safety data. If the Commission has concerns it can ask the Scientific Committee on Consumer Safety for an opinion. Nanomaterials used as colorants, preservatives or UV filters regulated in the Annexes, and uses that conform to Annex III, are outside this procedure. Everything else in the CPNP is a record, not a review.
CPNP and CPSR: which notification fields come out of the safety assessment
Article 13(1) lists what you notify. Look closely and much of it is copied from the safety assessment rather than invented in the portal. Our full CPNP field list covers every field; this table shows the ones that depend on the CPSR.
| CPNP field | Where the answer comes from in the CPSR | What goes wrong if you guess |
|---|---|---|
| Product category | The product type and use the assessor actually assessed (Part A, normal and reasonably foreseeable use; exposure) | A face serum notified as a body product, so the record and the assessment describe different things |
| Frame formulation, exact or range declaration | Part A, quantitative and qualitative composition | Declared figures that do not match the formula in the file |
| CMR substances (category 1A or 1B) | Part A toxicological profiles, checked against current CLP classifications | A missed reclassification, which is a restriction problem as well as a notification error |
| Nanomaterials | Supplier specifications gathered for Part A | No Article 16 notification six months ahead, which can push back your launch |
| pH (only below 3, above 10, or any hair dye) | Part A, physical and chemical characteristics, measured on the finished product | A target figure from the brief instead of a measured one |
| Labelling and pack photo | Part B, warnings and instructions of use | Artwork printed before the assessment, missing a warning the assessor requires |
This is the practical case for doing things in order. The Regulation only says both must be done before the product is placed on the market. It does not say which comes first. But brands that notify before the assessment end up guessing the answers, the assessor then reaches different ones, and the notification has to be corrected under Article 13(7). Do the safety assessment first and the notification becomes copying rather than guessing. Our frame formulation guide explains the formulation choice in detail.
Who reads your CPNP data, and what they do with it
Two groups can see a notification, and neither is reviewing safety when they open it.
- Competent authorities in every Member State see the product details and the labelling (Article 13(5)). They may use them only for market surveillance, market analysis, evaluation and consumer information. In practice the CPNP is how they find out who is responsible for a product and where its file is kept.
- Poison centres and similar bodies see everything, including the formulation (Article 13(6)). They may use it only for medical treatment. When a toddler drinks half a bottle of bath foam, the poison centre needs the composition in minutes. That is why the frame formulation exists.
Serious undesirable effects do not go through the CPNP either. Under Article 23, the Responsible Person and distributors report them without delay to the competent authority of the country where the effect happened, along with any corrective measures. The authority shares the report with other Member States, and the information should then feed back into the undesirable effects section of your CPSR.
How an authority actually checks product safety
Article 22 requires Member States to run in-market controls: checks on products and on the businesses behind them, through the Product Information File and, where appropriate, physical and laboratory tests on samples. National authorities also coordinate campaigns through PEMSAC, the EU platform of cosmetics market surveillance authorities, often around one category or one ingredient concern.
In our experience the sequence is predictable. Something triggers attention: a consumer complaint, a reaction report, a competitor complaint, a marketplace escalation, a customs referral or a lab result from a sampling campaign. The authority looks up the CPNP record, which gives it the Responsible Person, the file address and the contact person. It then writes asking for the Product Information File, which Article 11 requires you to keep readily accessible at that address, in a language the authority can easily understand, for ten years after the last batch is placed on the market.
From there everything depends on what arrives. A complete file with a well-reasoned CPSR usually closes the matter or narrows it to one question your assessor can answer. A file with gaps tends to widen the enquiry, because an inspector who finds one weak report will reasonably ask about the rest of the range. Under Article 25, where a product does not meet the safety assessment, file or notification requirements, the authority must require the Responsible Person to take appropriate measures, including corrective action, withdrawal or recall, within a deadline that reflects the risk. If you do not act, or the risk to health is serious, the authority acts itself, and serious-risk measures are shared with other countries and can appear on Safety Gate, the EU rapid alert system. Penalties for breaches are set nationally under Article 37.
Ask yourself
If an inspector emailed tomorrow asking for the file on your best seller, how long would it take you to send something you would be happy for a toxicologist to read?
What an inadequate safety assessment looks like
These are the problems we see most often when we review a CPSR that a brand already has:
- No named assessor. A report signed only with a company name, or not signed at all, fails Article 10(2) on its face. Our guide to who can sign a CPSR sets out the rules.
- A conclusion with no reasoning. Two paragraphs saying the product "is considered safe" is an opinion, not an assessment. Part B has to show how the assessor got there.
- The wrong exposure. A leave-on face serum assessed as a rinse-off product, or a lip product assessed with no allowance for swallowing.
- No challenge test for a water-based product. Without it there is no evidence the preservative works in that formula.
- A period after opening with nothing behind it. A "12M" symbol needs stability and microbiological reasoning, not a borrowed figure.
- Restricted ingredients not checked. Annex limits and conditions, current CMR classifications, and fragrance materials against the right IFRA category.
- A report older than the formula. If a supplier or ingredient changed, the report describes a product you no longer sell. See when a CPSR needs updating.
- An empty undesirable effects section. Even when there have been none, the report should say so and be updated when that changes.
Notice that none of these mean the product is dangerous. A product can be entirely safe and its assessment still inadequate. The obligation is to have carried out a proper assessment, so a thin report is a breach in its own right. "Nobody has complained" is not a defence. It is usually the reason nobody has looked.
The "notification only" trap
There is a market for quick, cheap CPNP notifications with no questions asked about safety. If a provider offers to notify your range, or to act as your Responsible Person, without asking to see a CPSR, they are doing the easy obligation and leaving the real one undone. For the brand that can be worse than doing nothing, because a notified product is on the authorities' radar with a named Responsible Person and a file address. Any enquiry now has somewhere to land.
A variant of the same trap is the very short "safety assessment" produced without questions, sometimes with no identifiable assessor, sometimes recycled across products with only the name changed. Our guides to the risks of a cheap CPSR and choosing a safety assessor explain what to look for.
Already notified but never assessed? How to fix it
This is more common than brands admit. Be clear about the legal position first: a product on the market without a safety assessment does not comply with Article 10, and Article 5(2) requires the Responsible Person who has reason to believe a product is non-compliant to take corrective measures immediately, which can mean bringing it into conformity, withdrawing it or recalling it. So the fix needs to be quick and methodical.
- Stop launches, and hold back unassessed stock where you can. Every new product widens the gap, and every unit shipped without an assessment adds to the problem.
- List what you really sell, with the formulas your manufacturer uses today. This usually takes longer than expected, because formulas drift away from their paperwork.
- Prioritise by risk, not sales. Leave-on before rinse-off, face and eye area before body, anything for children, anything with actives, a high fragrance load or an SPF.
- Commission the assessments and expect findings. At least one reformulation, a shorter period after opening or a new warning is normal.
- Build the Product Information File as each report arrives, with the manufacturing description, GMP statement and claim evidence.
- Update the CPNP where the formulation, category or labelling changes, and replace artwork that is missing a warning Part B requires.
If an assessment shows that a product already sold presents a risk to health, Article 5(2) also requires you to tell the competent authorities straight away: those in the countries where you sold it and in the country where the file is kept. Our recall and withdrawal guide walks through it. A brand that does all this voluntarily is in a far stronger position than one doing it against an inspector's deadline.
A worked example: the facial oil that failed a file request
This is a composite of cases we have handled, not a single client. A small brand received a request for its Product Information File after a customer reported a reaction to a facial oil. It had two weeks and sent what it had. The authority came back with four problems:
- The CPSR named no assessor and was signed with a consultancy's company name.
- Part B was two paragraphs long, with no margins of safety and no explanation of the warnings.
- The exposure section described a body oil. The product was sold, and notified, as a face product.
- The Part A formula no longer matched the product: a carrier oil had been swapped 18 months earlier when a supplier ran short.
The CPNP record, meanwhile, was perfect. Category, formulation, contact person, labelling: all filled in correctly years before. It simply had nothing to do with whether the product was safe.
The brand commissioned a proper assessment within the extra time the authority allowed. The assessor found the new carrier oil had no antioxidant, the period after opening was not supported, and the product needed a warning about contact with the eyes. The oil was reformulated with tocopherol, the period after opening was shortened, the notification and artwork were updated, and the authority closed the matter. The brand then had its other eleven products assessed properly over the next two months.
A quick check before (and after) you notify
- A signed CPSR exists for this exact formula, with a named, qualified assessor.
- The CPNP category matches the product type and use that was assessed.
- The formulation, CMR and nanomaterial answers are copied from Part A, not from memory.
- Any nanomaterial needing Article 16 notification was notified six months before launch.
- The label carries every warning Part B requires, and that is the artwork you uploaded.
- The Product Information File sits at the address on the label and in the notification, ready to send.
- Someone owns the job of updating the CPSR and the CPNP when the formula, supplier or label changes.
Not sure whether you need a CPSR at all? Start with who needs a CPSR, and when. Pricing the notification side? Our breakdown of what CPNP notification really costs shows where the time goes, and CPNP login and access covers who should hold the keys. If you would rather have the assessment, file and notification done in the right order, our CPSR service starts with the safety assessment and our CPNP notification service finishes the job from it.
Related reading on the Phoenix blog
- What is CPNP? EU cosmetic product notification explained
- CPNP registration: why notification is not approval
- What information does the CPNP ask for? The full field list
- Who needs a CPSR report, and when?
- What is a CPSR? The complete guide
- CPSR Part B explained: inside the safety assessment
- The margin of safety in cosmetic toxicology
- PIF vs CPSR: what goes where
- The risks of a bargain CPSR
Myths we hear
- My CPSR was accepted when I notified. It was never submitted. The CPNP does not ask for the CPSR, so nothing was reviewed and nothing was accepted.
- If my formula had a problem, the portal would have flagged it. The portal checks that required fields are completed. It runs no safety check on ingredients, concentrations or restrictions.
- Poison centres see my formulation, so someone has vetted it. Poison centres may use the formulation only for medical treatment, for example when a child swallows the product. They do not assess it.
- No enquiry in five years means my file is fine. It means nobody has opened it yet. Authorities check files through in-market controls under Article 22, often years after launch.
- A safe product can't have a bad assessment. The legal duty is to carry out a proper safety assessment. A thin, unsigned or out-of-date report breaches Article 10 even if no one has reacted to the product.
What to do this week
- Pick your best-selling product and open its CPSR. Check that Part B names the safety assessor, states their qualification, and is signed and dated.
- Put the Part A formula next to the one your manufacturer actually makes today. Any difference, including a swapped supplier for the same INCI, needs the assessor's view.
- Compare the CPNP notification with the CPSR: category, formulation, CMR and nanomaterial answers should match the assessment exactly.
- Check the warnings on your current artwork against the warnings and instructions Part B requires, then compare that artwork with the labelling uploaded to the CPNP.
- Make sure every water-based product has a challenge test and that each period-after-opening symbol is supported by stability data.
- List any product that was notified before it was assessed, and book those assessments first, starting with leave-on, children's and eye-area products.
- Decide who will answer an authority's request for the Product Information File, and how quickly you could send it.
Frequently asked questions
Does the CPNP check product safety?
No. The CPNP checks that the required fields are filled in, but nobody reviews your formula or your safety report at notification. Product safety is established by the Cosmetic Product Safety Report, which must exist before the product is placed on the EU market.
Do I upload my CPSR to the CPNP?
No. The CPSR is never uploaded. It is part of the Product Information File, which the Responsible Person keeps at the address given on the label and in the notification, and sends to a competent authority on request.
Do I need a CPSR before I notify on the CPNP?
The Regulation requires both before the product is placed on the market, without fixing their order. In practice, finish the safety assessment first: the formulation, CMR, nanomaterial and labelling answers in the notification come from it, and guessing them means correcting the notification later.
Who can see my CPNP notification?
National competent authorities can see the product details and labelling for market surveillance. Poison centres and similar bodies also see the formulation, which they may use only for medical treatment. The notification is not published, and competitors cannot look it up.
Does a CPNP reference number prove my product is safe?
No. It proves the product was notified. The Commission's own CPNP guide says a successful notification does not mean the product complies with the Regulation. The evidence of safety is the signed CPSR in your Product Information File.
Who is allowed to carry out the safety assessment?
Article 10(2) requires the Part B assessment to be done by someone with a diploma or equivalent qualification from a university course in pharmacy, toxicology, medicine or a similar discipline, or a course a Member State recognises as equivalent. The report should name that person.
What happens if an authority asks for my Product Information File?
It will usually have found your details through the CPNP and will write to the Responsible Person with a deadline. If the file shows gaps, Article 25 lets it require corrective action, withdrawal or recall within a set time, and it can act itself if you do not.
I notified my products but never had them assessed. What now?
Act quickly. A product without a safety assessment does not comply with Article 10, and Article 5(2) requires immediate corrective measures, which can include withdrawing it until it is assessed. Stop launches, list the real current formulas, commission assessments starting with the highest-risk products, then update each notification and label.
Official sources and legislation
- Regulation (EC) No 1223/2009, Article 3: safety (as adopted, legislation.gov.uk)
- Regulation (EC) No 1223/2009, Article 5: obligations of responsible persons (as adopted, legislation.gov.uk)
- Regulation (EC) No 1223/2009, Article 10: safety assessment (as adopted, legislation.gov.uk)
- Regulation (EC) No 1223/2009, Annex I: cosmetic product safety report (as adopted, legislation.gov.uk)
- Commission Implementing Decision 2013/674/EU: guidelines on Annex I (legislation.gov.uk)
- Regulation (EC) No 1223/2009, Article 11: product information file (as adopted, legislation.gov.uk)
- Regulation (EC) No 1223/2009, Article 13: notification (as adopted, legislation.gov.uk)
- Regulation (EC) No 1223/2009, Article 16: nanomaterials (as adopted, legislation.gov.uk)
- Regulation (EC) No 1223/2009, Article 22: in-market control (as adopted, legislation.gov.uk)
- Regulation (EC) No 1223/2009, Article 23: serious undesirable effects (as adopted, legislation.gov.uk)
- Regulation (EC) No 1223/2009, Article 25: non-compliance by the responsible person (as adopted, legislation.gov.uk)
- Regulation (EC) No 1223/2009, Article 37: penalties (as adopted, legislation.gov.uk)
- European Commission: Cosmetics legislation, Regulation (EC) No 1223/2009 and consolidated text
- European Commission: Guide to using CPNP for Responsible Persons and distributors, Article 13 (PDF)
- European Commission: Cosmetic Products Notification Portal (CPNP)
- European Commission: Cosmetics market surveillance, PEMSAC and serious undesirable effects
- European Commission: Nanomaterials in cosmetics
- Scientific Committee on Consumer Safety (SCCS)
- Safety Gate: the EU rapid alert system for dangerous non-food products
Join the conversation